Feasibility and Performance of Hemoglobin A1C Self-Testing During COVID-19 Among African Americans With Type 2 Diabetes
Authors:
- Jihun WooJWJihun Woo
- Erum Z. WhyneEWErum Z. Whyne
- Jaylen I. WrightJWJaylen I. Wright
- H. Matthew LehrerHLH. Matthew Lehrer
- Taha A. AlhalimiTATaha A. Alhalimi
- Tianyu WangTWTianyu Wang
- Victoria C. SabaVSVictoria C. Saba
- Susan K. DuboisSDSusan K. Dubois
- Hirofumi TanakaHTHirofumi Tanaka
- Sharon A. BrownSBSharon A. Brown
- Mary A. SteinhardtMSMary A. Steinhardt
- 4 June 2022
- journal article
- research article
- Published by SAGE Publications in The Science of Diabetes Self-Management and Care
- Vol. 48 (4) , 204-212
Abstract
Purpose: The purpose of the study was to determine the feasibility of implementing A1C self-testing at home using the A1CNow® Self Check and to compare the accuracy of the A1CNow to a reference standard in African Americans with type 2 diabetes (T2D). Methods: African American adults with T2D were recruited from 13 different churches (N = 123). Phase 1, conducted during the early phase of the COVID-19 pandemic, examined the feasibility of A1C assessment using the A1CNow performed at home by untrained participants. Phase 2, conducted when in-person research resumed, compared A1C values concurrently measured using the A1CNow and the DCA Vantage™ Analyzer (reference standard) collected by research staff at church testing sites. Results: In Phase 1, 98.8% of participants successfully completed at least 1 at-home A1C test; the overall failure rate was 24.7%. In Phase 2, the failure rate of staff-performed A1CNow testing was 4.4%. The Bland-Altman plot reveals that A1CNow values were 0.68% lower than DCA values, and the mean differences (A1CNow minus DCA) ranged from −2.6% to 1.2% with a limit of agreement between −1.9% to 0.5%. Conclusions: A1C self-testing is feasible for use in community settings involving African American adults with T2D. The A1CNow Self-Check underestimated A1C values when compared with the reference standard. Ongoing improvements in point-of-care devices have the potential to expand research and clinical care, especially in underserved communities.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK123146)
This publication has 20 references indexed in Scilit:
- Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012JAMA, 2015
- Selecting an A1C Point-of-Care InstrumentDiabetes Spectrum, 2015
- Understanding Bland Altman analysisBiochemia Medica, 2015
- Point-of-Care HbA1c Testing With the A1cNow Test Kit in General Practice Dental ClinicsPoint of Care: The Journal of Near-Patient Testing & Technology, 2014
- Assessment of the Performance of A1CNow + and Development of an Error Grid Analysis Graph for Comparative Hemoglobin A1c MeasurementsDiabetes Technology & Therapeutics, 2014
- Accuracy and Clinical Utility of a Point-of-Care HbA1c, Testing DevicePostgraduate Medicine, 2013
- Evaluation of an Over-the-Counter Glycated Hemoglobin (A1C) Test KitJournal of Diabetes Science and Technology, 2010
- Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalencePopulation Health Metrics, 2010
- An Overview of Dual Sensory Impairment in Older Adults: Perspectives for RehabilitationTrends in Amplification, 2007
- Clinical Evaluation of a Rapid A1C Test (A1cNow) for Home UsePoint of Care: The Journal of Near-Patient Testing & Technology, 2006